Castle Biosciences, Inc. CSTL
$34.96
$1.524.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 357.28M | 339.92M | 344.23M | 343.53M | 346.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 357.28M | 339.92M | 344.23M | 343.53M | 346.27M |
| Cost of Revenue | 81.25M | 75.18M | 71.03M | 68.90M | 65.80M |
| Gross Profit | 276.03M | 264.74M | 273.20M | 274.63M | 280.47M |
| SG&A Expenses | 243.66M | 235.60M | 229.32M | 222.56M | 217.15M |
| Depreciation & Amortization | 9.03M | 8.74M | 14.74M | 16.80M | 16.80M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 389.39M | 373.21M | 366.94M | 358.36M | 349.22M |
| Operating Income | -32.11M | -33.29M | -22.71M | -14.83M | -2.95M |
| Income Before Tax | -19.20M | -17.66M | -29.51M | -18.92M | -10.25M |
| Income Tax Expenses | 212.00K | -4.82M | -5.36M | -6.68M | -781.00K |
| Earnings from Continuing Operations | -19.42 | -12.83 | -24.16 | -12.24 | -9.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.42M | -12.83M | -24.16M | -12.24M | -9.47M |
| EBIT | -32.11M | -33.29M | -22.71M | -14.83M | -2.95M |
| EBITDA | -14.70M | 3.56M | 19.88M | 29.74M | 39.54M |
| EPS Basic | -0.65 | -0.43 | -0.84 | -0.42 | -0.32 |
| Normalized Basic EPS | -0.47 | -0.48 | -0.24 | -0.05 | 0.22 |
| EPS Diluted | -0.66 | -0.44 | -0.85 | -0.46 | -0.36 |
| Normalized Diluted EPS | -0.47 | -0.48 | -0.24 | -0.07 | 0.20 |
| Average Basic Shares Outstanding | 118.69M | 117.21M | 115.93M | 114.72M | 113.49M |
| Average Diluted Shares Outstanding | 118.69M | 117.84M | 116.56M | 117.43M | 117.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |